A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study Designed to Compare the Safety and Pharmacokinetics of Orally Administered Superoxide Dismutase Mimetic GC4711 With Intravenously Administered Superoxide Dismutase Mimetic GC4419 (Part 1), With Assessment of Food Effect (Part 2), in Healthy Volunteers

Trial Profile

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study Designed to Compare the Safety and Pharmacokinetics of Orally Administered Superoxide Dismutase Mimetic GC4711 With Intravenously Administered Superoxide Dismutase Mimetic GC4419 (Part 1), With Assessment of Food Effect (Part 2), in Healthy Volunteers

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs GC 4419 (Primary) ; GC 4711 (Primary)
  • Indications Cancer; Head and neck cancer; Stomatitis
  • Focus Adverse reactions; First in man
  • Sponsors Galera Therapeutics
  • Most Recent Events

    • 21 Jun 2017 Planned End Date changed from 1 Apr 2018 to 1 Dec 2017.
    • 21 Jun 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Dec 2017.
    • 21 Jun 2017 Planned initiation date changed from 1 May 2017 to 1 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top